Table 1 Clinical characteristics of multifocal and oligofocal osteonecrosis (ON) in 254 patients with ON
From: Clinical characteristics and role of whole-body bone scan in multifocal osteonecrosis
Multifocal ON (n = 26) | Oligofocal ON (n = 228) | Any ON (N = 254) | p-value | |
|---|---|---|---|---|
Age (years) | 42.8 ± 14.3 | 50.9 ± 15.4 | 50.0 ± 15.4 | 0.011 |
Sex (M/F) | 15 (57.7)/11 (42.3) | 137 (60.1)/91 (39.9) | 152 (59.8)/102 (40.2) | 0.835 |
Smoking (yes) | 7 (26.9) | 94 (41.2) | 101 (39.8) | 0.205 |
Alcohol use (excessive) | 10 (38.5) | 104 (45.6) | 114 (44.9) | 0.538 |
Diabetes mellitus | 3 (11.5) | 11 (4.8) | 14 (5.5) | 0.162 |
Hypertension | 10 (38.5) | 54 (23.7) | 64 (25.2) | 0.150 |
Trauma | 1 (3.8) | 37 (16.2) | 38 (15.0) | 0.007 |
Symptom sites (n) | 1.92 ± 1.26 | 1.26 ± 0.44 | 1.33 ± 0.61 | 0.014 |
Symptom duration (months) | 7.0 ± 9.3 | 7.5 ± 13.7 | 7.4 ± 13.3 | 0.855 |
Comorbidity | 18 (69.2) | 91 (39.9) | 109 (42.9) | 0.006 |
Comorbidity duration (years) | 6.37 ± 6.77 | 6.74 ± 6.80 | 6.68 ± 6.77 | 0.833 |
Use of CS | 16 (61.5) | 50 (21.9) | 66 (26.0) | < 0.001 |
Maximal dose of CS | 284.4 ± 427.3 | 154.0 ± 317.0 | 185.6 ± 347.9 | 0.273 |
Cumulative dose of CS | 5310.7 ± 5359.6 | 5704.8 ± 7664.7 | 5612.8 ± 7153.0 | 0.859 |
Use of immunosuppressive agents | 11 (42.3) | 40 (17.5) | 51 (20.1) | 0.007 |
Osteoporosis | 1 (3.8) | 12 (5.3) | 13 (5.1) | > 0.999 |
Use of BP | 1 (3.8) | 10 (4.4) | 11 (4.3) | > 0.999 |
BP duration (months) | 24 | 49.7 ± 18.5 | 47.4 ± 19.2 | |
ON sites confirmed by X-ray and MRI | 3.04 ± 1.42 | 1.52 ± 0.53 | 1.68 ± 0.81 | < 0.001 |
ON sites confirmed by bone scan | 4.15 ± 2.05 | 1.27 ± 0.53 | 1.57 ± 1.20 | < 0.001 |